The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
Abstract
Purpose: This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of the oral platinum analog satraplatin in patients with metastatic castrate-refractory prostate cancer (CRPC) experiencing progression after one prior chemotherapy regimen. Patients and Methods: Nine hundred fifty patients were randomly assigned (2:1) to receive oral satraplatin (n = 635) 80 mg/m 2 on days 1 to 5 of a 35-day cycle and prednisone 5 mg twice daily or placebo (n = 315) and prednisone 5 mg twice daily. Primary end points were progression-free survival and overall survival (OS). The secondary end point was time to pain progression (TPP). Results: A 33% reduction (hazard ratio [HR] = 0.67; 95% CI, 0.57 to 0.77; P < .001) was observed in the risk of progression or death with satraplatin versus placebo. This effect was maintained irrespective of prior docetaxel treatment. No difference in OS was seen between the satraplatin and placebo arms (HR = 0.98; 95% CI, 0.84 to 1.15; P = .80). Compared with placebo, satraplatin significantly reduced TPP (HR = 0.64; 95% CI, 0.51 to 0.79; P < .001). Satraplatin was generally well tolerated, although myelosuppression and GI disorders occurred more frequently with satraplatin. Conclusion: Oral satraplatin delayed progression of disease and pain in patients with metastatic CRPC experiencing progression after initial chemotherapy but did not provide a significant OS benefit. Satraplatin was generally well tolerated. These results suggest activity for satraplatin in patients with CRPC who experience progression after initial chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
The McGill Pain Questionnaire: Major properties and scoring methods
Melzack, R. (1975) · Pain · doi:10.1016/0304-3959(75)90044-5 · Cited by 6,845
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 1×
“Median survival time in patients with metastatic CRPC has been reported to be 12 to 19 months.(2,3,30,31) Patients often have severe symptoms, including substantial pain from bone metastases, worsening functional status, and/or fatigue.”
BackgroundSelf-citationA Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Self-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Multiple Comparison Procedures
Hochberg, Y., & Tamhane, A. C. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316672 · Cited by 2,389
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Self-citationModelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Multiple Comparison Procedures
(2013) · An Introduction to Statistical Concepts · doi:10.4324/9780203137819-17 · Cited by 2,109
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580
Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationSurvival Analysis with Long-Term Survivors
Wassell, J. T., Maller, R. A., & Zhou, X. (1998) · Journal of the American Statistical Association · doi:10.2307/2669877 · Cited by 339
Use of the McGill Pain Questionaire in the assessment of cancer pain: Replicability and consistency
Graham, C., Bond, S. S., Gerkovich, M. M., & Cook, M. R. (1980) · Pain · doi:10.1016/0304-3959(80)90081-0 · Cited by 243
Kèlland, L. R., Abel, G., McKeage, M. J., Jones, M., Goddard, P. M., Valenti, M., Murrer, B. A., & Harrap, K. R. (1993) · PubMed · Cited by 224
Modelling Survival Data in Medical Research.
D'Agostino, R. B., & Collett, D. (1995) · Journal of the American Statistical Association · doi:10.2307/2291354 · Cited by 223
Sternberg, C. N., Whelan, P., Hetherington, J., Paluchowska, B., Slee, P. H. T. J., Vekemans, K., van Erps, P., Theodore, C., Koriakine, O., Oliver, T., et al. (2005) · Oncology · doi:10.1159/000084201 · Cited by 206
Self-citationWhen You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival
Panageas, K. S., Ben-Porat, L., Dickler, M. N., Chapman, P. B., & Schrag, D. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk091 · Cited by 182
Modelling Survival Data in Medical Research. By D. Collett (Chapman & Hall, 1994) £19.99
Macdonald, A. S. (1995) · British Actuarial Journal · doi:10.1017/s1357321700001173 · Cited by 122
Management of Advanced Prostate Cancer After First-Line Chemotherapy
Berthold, D., Sternberg, C. N., & Tannock, I. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1435 · Cited by 101
Self-citationTwentyman, P. R. (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90452-4 · Cited by 78
Latif, T., Wood, L. S., Connell, C. F., Smith, D. C., Vaughn, D. J., Lebwohl, D., & Peereboom, D. (2004) · Investigational New Drugs · doi:10.1023/b:drug.0000047109.76766.84 · Cited by 71
Bernhard, J., Zahrieh, D., Castiglione‐Gertsch, M., Hürny, C., Gelber, R. D., Forbes, J., Murray, E., Collins, J. P., Aebi, S. P., Thurlimann, B. J. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5393 · Cited by 62
Oh, W. K., Manola, J. B., Babcic, V., Harnam, N., & Kantoff, P. W. (2006) · Urology · doi:10.1016/j.urology.2006.01.006 · Cited by 53
Joshua, A. M., Nordman, I. I. C., Venkataswaran, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4713 · Cited by 5
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citation
Metadata
- Authors
- Sternberg, C. N., Petrylak, D. P., Sartor, O., Witjes, J. A., Demkow, T., Ferrero, J.-M., Eymard, J.-C., Falcon, S., Calabrò, F., James, N., Bodrogi, I., Harper, P., Wirth, M., Berry, W., Petrone, M. E., McKearn, T. J., Noursalehi, M., George, M., & Rozencweig, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-11-10
- Volume
- 27
- Issue
- 32
- Pages
- 5431-5438
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2130803372
- Cited by
- 340
- References
- 26
- FWCI
- 34.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.